An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
- PMID: 21687579
- PMCID: PMC3114080
- DOI: 10.1155/2011/820816
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
Abstract
Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical treatment of overactive bladder. They offer significant improvements in symptoms and patients' quality of life. Antimuscarinics are generally well tolerated with mild and predictable side effects. Available antimuscarinics have small, yet statistically significant, differences in their efficacy and tolerability profiles. In clinical practice, finding the agent that offers the optimum balance of efficacy and side effects for an individual patient remains the major challenge.
Similar articles
-
The medical treatment of overactive bladder, including current and future treatments.Expert Opin Pharmacother. 2011 May;12(7):1041-55. doi: 10.1517/14656566.2011.554399. Epub 2011 Feb 8. Expert Opin Pharmacother. 2011. PMID: 21299469 Review.
-
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.Eur Urol. 2019 Dec;76(6):767-779. doi: 10.1016/j.eururo.2019.07.010. Epub 2019 Aug 13. Eur Urol. 2019. PMID: 31416636 Review.
-
Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?Low Urin Tract Symptoms. 2018 May;10(2):158-166. doi: 10.1111/luts.12153. Epub 2016 Dec 23. Low Urin Tract Symptoms. 2018. PMID: 28009939
-
Fesoterodine for the treatment of urinary incontinence and overactive bladder.Ther Clin Risk Manag. 2009;5:869-76. doi: 10.2147/tcrm.s6483. Epub 2009 Nov 18. Ther Clin Risk Manag. 2009. PMID: 19956551 Free PMC article.
-
Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.Pharmacol Ther. 2018 Sep;189:130-148. doi: 10.1016/j.pharmthera.2018.04.010. Epub 2018 Apr 27. Pharmacol Ther. 2018. PMID: 29709423 Review.
Cited by
-
Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3. Clin Drug Investig. 2013. PMID: 23208320 Clinical Trial.
-
A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.J Clin Diagn Res. 2015 Mar;9(3):FC05-9. doi: 10.7860/JCDR/2015/11884.5677. Epub 2015 Mar 1. J Clin Diagn Res. 2015. PMID: 25954630 Free PMC article.
-
Pharmacology of the lower urinary tract: update on LUTS treatment.Ther Adv Urol. 2020 May 13;12:1756287220922425. doi: 10.1177/1756287220922425. eCollection 2020 Jan-Dec. Ther Adv Urol. 2020. PMID: 32489425 Free PMC article. Review.
-
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.Low Urin Tract Symptoms. 2020 Jan;12(1):68-80. doi: 10.1111/luts.12286. Epub 2019 Sep 30. Low Urin Tract Symptoms. 2020. PMID: 31571403 Free PMC article. Clinical Trial.
-
Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.Clin Drug Investig. 2014 Jan;34(1):27-35. doi: 10.1007/s40261-013-0146-1. Clin Drug Investig. 2014. PMID: 24178236 Free PMC article. Clinical Trial.
References
-
- Hashim H, Abrams P. Overactive bladder: an update. Current Opinion in Urology. 2007;17(4):231–236. - PubMed
-
- Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. European Urology. 2011;59(3):377–386. - PubMed
-
- Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourology and Urodynamics. 2010;29(1):112–115. - PubMed
-
- Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83(5):259–269. - PubMed
-
- Andersson KE, Chappie CR. Oxybutynin and the overactive bladder. World Journal of Urology. 2001;19(5):319–323. - PubMed
LinkOut - more resources
Full Text Sources